Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTAFLUOR BENOX vs CLENPIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
FDA: For topical ophthalmic anesthesia and as a disclosing agent during ophthalmic procedures (e.g., tonometry, gonioscopy, removal of foreign bodies, sutures).,Off-label: No well-established off-label uses.
Cleansing of the colon as a preparation for colonoscopy in adults
1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
Terminal elimination half-life: 1.0–1.5 hours in adults with normal renal function; prolonged to 6–10 hours in severe renal impairment (Cr Cl <30 m L/min).
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Systemic absorption is minimal after ophthalmic administration. Benoxinate is hydrolyzed by plasma esterases; metabolites are excreted renally. Fluorescein is metabolized via glucuronidation in the liver and excreted primarily in urine.
Bisacodyl (picosulfate) is hydrolyzed by colonic bacteria to its active metabolite BHPM; magnesium citrate acts locally.
Renal: ~80% as unchanged drug; biliary/fecal: ~20% as metabolites (glucuronide conjugates).
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
~40–45% bound to plasma proteins (primarily albumin).
Sodium picosulfate: <5% bound to plasma proteins
Vd: 1.2–1.8 L/kg (total body water distribution with moderate tissue binding; higher Vd may reflect extensive extravascular distribution).
Sodium picosulfate: Vd ~0.2 L/kg (confined mainly to extracellular fluid, low tissue penetration)
Topical ophthalmic: minimal systemic absorption (<1% of dose enters systemic circulation).
Oral (sodium picosulfate): low systemic bioavailability (<10%) due to extensive first-pass activation in colon; magnesium citrate is a locally active osmotic agent with negligible systemic absorption
No dose adjustment required; systemic absorption minimal.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-59 m L/min/m²: reduce total prucalopride dose to 5 mg (i.e., single administration only).
No dose adjustment required; systemic absorption minimal.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild to moderate impairment (Child-Pugh A or B).
Not recommended for pediatric use; safety and efficacy not established.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
No specific dose adjustment; use with caution due to possible increased sensitivity.
No specific dose adjustment required solely based on age. Consider renal function (e GFR) and overall frailty; use conservative dosing in elderly with renal impairment (see renal_adjustment).
WARNING: CORNEAL TOXICITY AND IRREVERSIBLE CORNEAL DAMAGE. Prolonged use of topical anesthetics, including ALTAFLUOR BENOX, can result in delayed healing, corneal erosion, ulceration, perforation, and permanent vision loss. Use only for short-term procedures in a controlled clinical setting. Do not dispense to patients for self-administration.
WARNING: RISK OF SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. CLENPIQ can cause significant fluid and electrolyte shifts, which may lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. Monitor and correct electrolytes before use in patients at risk.
For topical ophthalmic use only. Not for injection.,Prolonged use may cause corneal toxicity; avoid repeated instillation.,Patients should avoid touching or rubbing the eye until anesthesia wears off.,Use with caution in patients with known hypersensitivity to ester-type anesthetics or fluorescein.,May cause transient stinging, burning, or conjunctival hyperemia.,Soft contact lenses should be removed before application and may be stained by fluorescein.
Risk of fluid and electrolyte abnormalities,Cardiac arrhythmias due to electrolyte imbalance,Seizures associated with electrolyte abnormalities,Renal impairment,Mucosal ulceration,Use with caution in patients with impaired gag reflex, reflux, or aspiration risk,Colonic mucosal aphthous ulcerations
Known hypersensitivity to benoxinate, fluorescein, or any component of the formulation.,Prolonged use (not indicated for repeated or long-term treatment).,Use in patients with corneal abrasions or epithelial defects (may delay healing).
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Hypersensitivity to any component,Severe renal impairment (e GFR <30 m L/min/1.73m²)
No specific food interactions. Avoid alcohol as it may increase risk of dizziness or syncope during eye procedures.
Avoid solid food during bowel preparation. Only clear liquids (water, clear broth, black coffee/tea, clear fruit juices without pulp, gelatin, popsicles) are permitted. Do not consume milk, cream, or any dairy products. Avoid red or purple colored liquids that may be mistaken for blood during colonoscopy. Do not consume alcohol.
ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. No teratogenic effects are expected in any trimester. Benoxinate is an ester-type local anesthetic; systemic absorption is minimal. No known teratogenic risk.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to pregnant rats during organogenesis at doses up to 1.2 times the human dose (based on body surface area) did not produce fetal harm. However, because animal studies are not always predictive of human response, CLENPIQ should be used during pregnancy only if clearly needed. During the first trimester, consider alternative bowel preparation to avoid any theoretical risk. In second and third trimesters, use only if potential benefit justifies potential risk to fetus.
Minimal systemic absorption of fluorescein and benoxinate after topical ophthalmic use suggests negligible excretion into breast milk. M/P ratio is not applicable. Generally considered compatible with breastfeeding.
Excretion in human milk unknown. M/P ratio not available. Because many drugs are excreted in human milk, caution should be exercised when CLENPIQ is administered to a nursing woman. Consider temporary discontinuation of breastfeeding during the 24-hour period after CLENPIQ administration.
No dose adjustments needed. Pharmacokinetic changes in pregnancy do not affect topical ophthalmic drug delivery. Use standard adult dose, 1-2 drops prior to procedure.
No dose adjustment recommendations available due to lack of pharmacokinetic studies in pregnancy. However, physiological changes in pregnancy (increased plasma volume, renal blood flow) may affect drug disposition; use lowest effective dose and ensure adequate hydration. No specific dose reduction recommended.
ALTAFLUOR BENOX (benzocaine 20% and fluorescein 0.25%) ophthalmic solution is used for corneal anesthesia and fluorescein staining. Apply 1-2 drops topically before procedures. Avoid prolonged use as benzocaine can cause corneal toxicity and delay healing. Fluorescein may stain soft contact lenses permanently; remove before use. Use with caution in patients with sulfonamide allergy (possible cross-reactivity with fluorescein). After use, patients should not rub eyes to prevent corneal abrasion.
CLENPIQ (sodium picosulfate, magnesium oxide, and citric acid) is a colonoscopy preparation. Ensure adequate hydration before, during, and after use. Common adverse effects include nausea, vomiting, and abdominal distension. Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min), gastrointestinal obstruction, ileus, or known hypersensitivity. Avoid use within 1 hour of antacids or medications that affect gastrointestinal motility.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Temporary blurred vision and stinging may occur; avoid driving until vision clears.,Do not use more often or longer than prescribed to prevent eye damage.,Tell your doctor if you have sulfa allergy or if you are pregnant or breastfeeding.
Take CLENPIQ as a split-dose regimen: one bottle the evening before and one bottle the morning of the colonoscopy.,Do not take any other laxatives or bowel preparations concurrently.,Stay hydrated by drinking clear liquids before and after each dose.,Do not eat solid food during the preparation period; only clear liquids are allowed.,Common side effects include nausea, bloating, and abdominal cramps; contact your doctor if severe or persistent.,Avoid driving or operating machinery if you feel dizzy or lightheaded.,Inform your doctor of all medications, especially diuretics, ACE inhibitors, ARBs, NSAIDs, or any drugs affecting kidney function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTAFLUOR BENOX vs CLENPIQ, answered by our medical review team.
ALTAFLUOR BENOX is a Ophthalmic Diagnostic Agent with Anesthetic that works by ALTAFLUOR BENOX is a combination of benoxinate, a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, stabilizing the neuronal membrane and inhibiting the initiation and conduction of nerve impulses, and fluorescein, a fluorescent dye that stains epithelial defects in the cornea. Local anesthetic effect occurs within seconds.. CLENPIQ is a Laxative that works by Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTAFLUOR BENOX and CLENPIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTAFLUOR BENOX is: 1-2 drops of 0.4% benoxinate hydrochloride ophthalmic solution instilled into the conjunctival sac prior to diagnostic procedures or surgery.. The standard adult dose of CLENPIQ is: Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTAFLUOR BENOX and CLENPIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTAFLUOR BENOX is classified as Category C. ALTAFLUOR BENOX contains fluorescein sodium and benoxinate hydrochloride. Fluorescein is not systemically absorbed in significant amounts after topical ophthalmic administration. N. CLENPIQ is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.